Key facts
- This page summarizes Dipan Patel's Form 4 filing for Amneal Pharmaceuticals, Inc. (AMRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Nov 2023, 18:21.
Dipan Patel - 07 Nov 2023 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)
- Reporting relationship
- Member of 13D Group
- Issuer ticker
- AMRX
- Reported as of
- 07 Nov 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Dipan Patel
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Dipan Patel filed Form 4 for Amneal Pharmaceuticals, Inc. (AMRX) on 08 Nov 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMRX
transaction
Class A Common Stock
Other
- Transaction value
- Shares
- +26,905,073
- Change %
- Price
- Shares after
- 26,905,073
- Date
- 07 Nov 2023
- Ownership
- By Trusts
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AMRX
transaction
Derivative
Class B Common Stock and Common Units
Other
- Transaction value
- Shares
- -26,905,073
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2023
- Ownership
- By Trusts
- Underlying class
- Class A Common Stock
- Underlying amount
- 26,905,073
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On November 7, 2023, Amneal Pharmaceuticals, Inc. (formerly known as Amneal NewCo Inc.) (the "Issuer") became the successor of Amneal Intermediate Inc. (formerly known as Amneal Pharmaceuticals, Inc.) ("Old PubCo") pursuant to merger transactions, in which a subsidiary of the Issuer merged with and into Old PubCo with Old PubCo surviving and, immediately following such merger, a subsidiary of the Issuer merged with and into Amneal Pharmaceuticals, LLC ("AP"), an indirect subsidiary of the Issuer, with AP surviving. The transactions resulted in the Issuer becoming a parent holding company of Old PubCo and AP. As a result of the transactions, there is a single class of stock of the Issuer outstanding, and the proportionate economic and voting rights of security holders in the Issuer are identical to the direct and indirect economic and voting rights held in Old PubCo and AP prior to the transactions.
Footnote F2
Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration.
Footnote F3
The Issuer of the Common Units is Amneal Pharmaceuticals, LLC.